Archive for the 'Lupus' Category
Lupus May Be Caused By Abnormal ‘Editing’ Of Gene Messages
Researchers at Wake Forest University have uncovered evidence that the abnormal “editing” of gene messages in a type of white blood cell may be behind the development of lupus. Scientists hope the finding will lead to earlier diagnosis, a way to monitor patients’ response to therapy and possibly a new way to treat the disease.Original post by Diabetes Notes
No commentsLupus Under The Spotlight: U.S. Congress Shows Support For Women’s Health Issues
The Alliance for Lupus Research (ALR) commends the Senate on its passage of a resolution supporting the goals and ideals of National Women’s Health Week that begins annually on Mother’s Day.Original post by Diabetes Mine
No commentsTwo Groundbreaking Scientists Share America’s Largest Medicine Prize
America’s largest prize for work in medicine, amounting to half a million dollars, is shared this year by two scientists, Elizabeth Blackburn of the University of California, San Francisco and Joan Streitz of Yale University, for their groundbreaking work in molecular research that opens up development of new and effective treatments for a range of diseases.Original post by SharpBrains
No commentsGenentech And Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study Of Rituxan In Systemic Lupus Erythematosus
Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) that a Phase II/III study of Rituxan® (rituximab) for systemic lupus erythematosus (SLE, commonly called lupus) did not meet its primary endpoint defined as the proportion of Rituxan treated patients who achieved a major clinical response (MCR) or partial clinical response (PCR) measured by BILAG, a lupus activity response index, compared to placebo at 52 weeks. The study also did not meet any of the six secondary endpoints.Original post by Diabetes Update
No commentsRigel’s R788 Slows Progression Of Murine Lupus In Preclinical Studies
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced today that its lead product candidate, R788, has successfully treated lupus prone mice and significantly improved their survival as reported in a recently published study of the drug candidate. R788 (fostamatinib disodium) is an orally bioavailable syk kinase inhibitor, which has shown clinically significant results in treating patients with rheumatoid arthritis and immune thrombocytopenic purpura in clinical trials.Original post by Diabetes Notes
No commentsStatement From The Lupus Foundation Of America Regarding The Release Of Top-Line Results From A Study Of Rituxan For The Treatment Of Lupus
Preliminary results were released from a late-stage clinical trial of Rituxan (rituximab) for the treatment of lupus. The study did not meet its primary or secondary endpoints of clinically reducing the severity of SLE (systemic lupus erythematosus) in people with moderate disease. The findings are initial results from a Phase II/III study conducted by Genentech, Inc., known as the EXPLORER study. Rituxan is approved by the U.S.Original post by Diabetes Notes
No commentsHuman Genome Sciences Completes Enrollment In First Of Two Phase 3 Lymphostat-B(R) Trials
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has completed enrollment and initial dosing in BLISS-52, one of two pivotal Phase 3 clinical trials of LymphoStat-B(R) (belimumab) in patients with active systemic lupus erythematosus (SLE). LymphoStat-B is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006. “We continue to be excited by LymphoStat-B’s potential.Original post by aiming for grace
No commentsLupus Foundation Of America Seeks Funding Proposals For Research Studies On Childhood Lupus, Nervous System Involvement, And More
The Lupus Foundation of America (LFA) is seeking proposals for up to $1.5 million in grant funding for basic, clinical, or translational research studies on lupus, an unpredictable and potentially fatal autoimmune disease. The purposes of the studies are to: accelerate ongoing research; directly sponsor novel approaches; and develop experimental prototypes.Original post by Diabetes Update
No comments$6.8M Awarded To Researchers Worldwide By The Alliance For Lupus Research
The Alliance for Lupus Research (ALR) recently announced that it will award nearly $7 million to researchers around the world. “The ALR is very proud to announce, during National Minority Health Month, that with our 2008 class of grantees the ALR has funded more than 100 research projects, and committed more than $50 million to research, since our founding in 1999,” says ALR President Barbara Boyts. For a full list of grantees, visit the ALR’s website, Original post by Diabetes Update
No commentsNews From The Journal Of Clinical Investigation March 13, 2008
A new road to the autoantibodies that characterize lupusSystemic lupus erythematosus (SLE), commonly known as lupus, is a chronic autoimmune disease characterized by the inflammatory destruction of many organs, including the skin, joints, and kidneys. A hallmark of the disease is the production of IgG antibodies that target nucleic acid-associated proteins in the nucleus of the individual’s own cells (so called autoantibodies).Original post by Diabetes Notes
No comments